Logo

Kite's Tecartus Receives the US FDA's Approval as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Share this

Kite's Tecartus Receives the US FDA's Approval as the First and Only Car T for Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Shots:

  • The approval was based on a P-I/II ZUMA-3 study assessing Tecartus in adult patients aged ≥18yrs. with ALL whose disease is refractory to or has relapsed following first standard systemic therapy with remission of 12mos. or less- after 2L+ systemic therapy or at least 100 days after ASCT
  • Results: 65% of the evaluable patients achieved CR or CRi @median actual follow-up of 12.3 mos.; mDOR (13.6mos.); Grade 3 or higher CRS (26%); neurologic events (35%); well tolerated
  • Tecartus is the first and only CAR T-cell therapy approved for adults aged ≥18yrs. with ALL. The approval marks Kite’s fourth indication for its cell therapies and first in Leukemia

  | Ref: Gilead | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions